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Impact of glycemic control on aortic 
stiffness, left ventricular mass and diastolic 
longitudinal function in type 2 diabetes mellitus
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Abstract 
Background: Poor glycemic control is associated with impaired left ventricular (LV) diastolic function in patients with 
type 2 diabetes mellitus (T2DM). Inappropriate LV mass increase and accelerated aortic stiffening were suggested 
to participate on deterioration of diastolic function. The present study investigated the inter-relationships between 
glycemic control, early diastolic and systolic longitudinal velocity of mitral annulus, LV mass and aortic stiffness in 
T2DM patients free of cardiovascular disease and with preserved LV ejection fraction, and compared them with those 
observed in healthy volunteers of similar age and sex distribution.
Methods: 125 T2DM patients and 101 healthy volunteers underwent noninvasive measurement of systolic (s′) and 
early diastolic (e′) velocities of mitral annulus, LV mass, carotid-femoral pulse wave velocity (cfPWV) and local carotid 
blood pressure (BP).
Results: Forty-four (35.2%) T2DM patients had e′ velocity lower than that expected for age (against 7.9% in healthy 
volunteers; P < 0.0001), 34 (27.2%) had cfPWV higher than that expected for age and mean BP (against 5.9% in 
healthy volunteers; P < 0.0001), and 71 (56.8%) had LV mass higher than that expected for body size and stroke 
work (against 17.6% in healthy volunteers; P < 0.0001). Carotid systolic BP was higher in T2DM patients (124 ± 14 vs 
111 ± 11 mmHg; P < 0.0001). In multivariate analysis, e′ velocity was independently related to age, carotid BP and s′ 
velocity in healthy volunteers, and to male sex, age, carotid BP, heart rate and LV mass in T2DM. Glycosylated hemo-
globin (HbA1c) was independently related to cfPWV and LV mass in T2DM patients. T2DM patients with HbA1c ≥6.5% 
(N = 85) had higher cfPWV (P < 0.05), central BP (P = 0.01), prevalence of LV hypertrophy (P = 0.01) and lower e′ and 
s′ velocity (P = 0.001 and <0.05, respectively) as compared to those with HbA1c <6.5%.
Conclusions: One-third of T2DM patients with preserved LV ejection fraction has sign of subclinical LV diastolic 
dysfunction. HbA1c levels are positively associated with LV mass and aortic stiffness, both of which show a negative 
independent impact on early diastolic velocity e′, the latter through an increase in afterload. T2DM patients with sub-
optimal glycemic control (HbA1c ≥ 6.5%) have lower diastolic and systolic LV longitudinal performance, together with 
increased aortic stiffness and a higher prevalence of LV hypertrophy.
Keywords: Glycemic control, LV diastolic function, Aortic stiffness, LV mass, Arterio-ventricular coupling, Systo-
diastolic coupling
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Background
Left ventricular (LV) diastolic dysfunction is considered 
an early manifestation of diabetic heart disease [1–3], 
and type 2 diabetes mellitus (T2DM) and hyperglycemia 
play an important role in the development and prognosis 
of diastolic heart failure, i.e. heart failure with preserved 
ejection fraction [4, 5]. Poor glycemic control may affect 
diastolic function by several mechanisms [6]. Chronic 
increase in plasma glucose levels elicits increase in LV 
mass through cardiomyocyte hypertrophy, collagen dep-
osition and cross-linking [7–9]. Hyperglycemia also dam-
ages mitochondrial energy signaling, inhibits autophagic 
flux in hypertrophic cardiomyocytes [10] and enhances 
myocardial oxidative stress [11], all of which may result 
in a deterioration of LV diastolic performance. Finally, 
hyperglycemia induces collagen cross-linking in arte-
rial wall, thus accelerating large artery stiffening [12]. 
Increase in large artery stiffness and consequent increase 
in arterial load, above all in late-systolic load, affects the 
transition from myocardial contraction to relaxation, 
causing a slower rate of diastolic LV pressure fall [13, 
14]. Increased vascular load and wall stress stimulates LV 
hypertrophy and remodeling that can further deteriorate 
myocardial function.
LV diastolic function is determined by relaxation rate, 
restoring forces and passive compliance of LV wall. There 
is no single noninvasive measure that can describe all 
these mechanisms, yet the LV lengthening velocity e′, 
measured by tissue Doppler imaging, represents a valu-
able parameters of diastolic function as it reflects both 
relaxation and restoring forces [15, 16]. In addition, e′ 
velocity has been shown to be inversely related to serum 
concentration of procollagen type I carboxy-terminal 
propeptide [17], which is considered a marker of myocar-
dial collagen content [18]. Previous studies have reported 
reduced e′ velocity of mitral annulus in asymptomatic 
T2DM patients [19, 20] as well as an association between 
e′ velocity and poor glycemic control [19, 21]. They have 
also demonstrated an inverse relationship between e′ 
velocity and LV mass or arterial stiffness [22, 23] and a 
direct association between diastolic e′ and systolic s′ lon-
gitudinal velocities [23]. Yet, the mutual relationships 
between glycemic control, LV hypertrophy, arterial stiff-
ening, afterload, systolic performance and LV diastolic 
function were not clearly established in diabetic patients.
Therefore, the present cross-sectional study evaluated 
the inter-relationships between LV diastolic longitudinal 
velocity e′ and LV mass, aortic and carotid stiffness, cen-
tral blood pressure (BP), systolic velocity s′ and indicators 
of glycemic exposure (plasma levels of fasting glucose 
and glycosylated hemoglobin and duration of diabetes) 
in T2DM patients free of clinical cardiovascular disease 
and with preserved LV ejection fraction (EF). Observed 
associations were compared with those obtained in a 
group of healthy volunteers of comparable age and sex 
distribution.
Methods
Study population
We investigated two populations. The first population 
consisted of 125 T2DM patients (aged between 40 and 
71  years) free of clinical cardiovascular diseases, with 
preserved LV EF, without signs of diastolic heart fail-
ure and with normal glomerular filtration rate (≥60 mL/
min/1.73 m2). They were selected from those referred for 
a complete vascular and cardiac examination to the Clinic 
for Cardiometabolic Risk Prevention of the Department 
of Surgical and Medical Pathology, University of Pisa. The 
second population consisted of 101 apparently healthy 
volunteers, comparable for age and sex distribution, 
selected from those participating on the study Relation-
ship between Insulin Sensitivity and Cardiovascular Risk 
(RISC) [24]. In both groups, cardiovascular disease was 
excluded by clinical history, resting ECG and echocardiog-
raphy; on echocardiographic examination LV ejection frac-
tion was ≥52 and 54%, for men and women, respectively 
[25]. LV asynergy was absent and E/e′ ratio (index of fill-
ing pressure) was <13.0 [26]. Hypertension was defined as 
either systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg 
at two study visits, or current antihypertensive treatment. 
Antagonists of renin-angiotensin-aldosterone system 
(ACE inhibitors and ARBs) were the most frequently used 
anti-hypertensive agent, followed by beta-blockers. Diag-
nosis of T2DM was based on plasma glucose criteria (fast-
ing glucose ≥7  mmol/L or HbA1c ≥6.5% or 2-h glucose 
during oral-glucose tolerance test ≥11.1  mmol/L) [27]. 
Twenty-two T2DM patients were treated by diet, 94 by 
oral antidiabetic drugs, 7 by a combination of oral antidia-
betics and insulin and 2 by insulin only.
Study protocol
The protocol of the study followed the principles of the 
Declaration of Helsinki and was approved by the institu-
tional ethics committee (reference number: 3146/2010 
and 245/2015). All subjects gave their informed consent 
to participate.
Vascular examination
All study subjects underwent carotid ultrasound and 
measurement of carotid-femoral pulse wave velocity 
(cfPWV). Vascular examination was performed in the 
afternoon, 3  h after a light meal, in a quiet room with a 
stable temperature of 22°, after resting comfortably for at 
least 15 min in the supine position. All subjects were asked 
to abstain from cigarette smoking, caffeine and alcohol 
consumption and vigorous physical activity for 24 h.
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Carotid-femoral pulse wave velocity (cfPWV) was 
measured according to current guidelines using the Com-
plior device (Alam Medical, Vincennes, France). Regres-
sion equations obtained in a reference value population 
were used to calculate appropriate cfPWV value accord-
ing to age and mean BP for each study subjects [28]. In 
our laboratory, intra- and inter-individual variability 
of cfPWV measurement are 4.3  ±  2.8 and 5.1  ±  2.9%, 
respectively.
Carotid ultrasound was performed by a single opera-
tor (CM) on the right common carotid artery using an 
ultrasound scanner equipped with a 10 MHz linear probe 
(MyLab 70, Esaote, Genova, Italy) and implemented with 
a previously validated radiofrequency-based tracking 
of arterial wall that allows a real-time determination of 
common carotid distension  (QAS®) with high spatial and 
temporal resolution (sampling rate of 550 Hz on 32 lines) 
[29]. From the distension curves, one-point carotid PWV 
(ccaPWV) was calculated applying the Bramwell-Hill 
equation that relates the propagation velocity to arterial 
distensibility [30]. The local carotid pressure was esti-
mated by converting the distension curve to a pressure 
curve using a linear conversion factor and assuming that 
the difference between mean arterial pressure and dias-
tolic pressure is invariant along the arterial tree [31]. The 
peripheral BP needed for rescaling carotid waveforms 
was measured at the left brachial artery (Omron, Kyoto, 
Japan) during each acquisition of the distension curves. 
Local carotid pressure estimate by QAS was previously 
validated against applanation tonometry [29] and was 
used as a surrogate of central aortic pressure.
All radiofrequency-derived measures were averaged 
over 6 consecutive cardiac beats and the values used for 
statistical analysis represent a mean of three consecu-
tive acquisitions. In our laboratory intra-individual vari-
ability of common carotid artery distension by QAS was 
7.5 ± 4.6% [29].
Cardiac ultrasound
Cardiac ultrasound was performed by a single opera-
tor (CM) with a standard ultrasound system (MyLab 70, 
Esaote, Genova, Italy) equipped with a 3.5-MHz, phased-
array probe. LV EF was measured by biplane method of 
disks [25]. LV dimensions and wall thickness were meas-
ured in M-mode images and LV mass was calculated as 
recommended [32]. LV hypertrophy was considered 
when LV mass indexed for  height2.7 was >49  g/m2.7 in 
men and >45 g/m2.7 in women [25]. The ratio of observed 
LV mass and LV mass predicted for gender, body height 
and stroke work was calculated, and inappropriate 
increase in LV mass was considered when the ratio was 
>1.28 [33]. End-systolic stress corrected midwall shorten-
ing (ess-MWS) was calculated as described [34]. Stroke 
volume was assessed as the product of aortic valve cross-
sectional area and transaortic flow-velocity time integral. 
Transmitral flow pattern was obtained and velocity of 
early (E) and late (A) diastolic filling was measured and 
E/A ratio was calculated.
LV longitudinal velocities at mitral annular level, both 
at septal and lateral sides, were measured by color-guided 
pulsed-wave tissue Doppler in the apical four-chamber 
view. The sample volume was placed at the junction of 
the LV wall with the mitral annulus, and the cursor was 
aligned so that the angle of incidence between the Dop-
pler beam and the longitudinal motion of the LV was as 
close as possible to 0° [35]. From spectral traces, peak 
systolic longitudinal velocity (s′) and peak longitudi-
nal velocity during early diastolic filling (e′) were meas-
ured and averaged over five consecutive cardiac cycles. 
Reported values of s′ and e′ longitudinal velocities rep-
resent an average of septal and lateral sides. The ratio 
between transmitral E and e′ velocity (E/e′ ratio) was 
calculated [26]. The intra-individual variability of tissue 
Doppler measurements in our laboratory is 5.8 ± 4.3 and 
6.3 ± 4.8% for s′ and e′ velocity, respectively.
Since e′ velocity depends strongly on age, a linear 
regression equation describing the relationship between 
age and e′ velocity in 101 healthy volunteers was applied 
to calculate the age-related normal e′ value and the 
respective lower 95% tolerance interval in each study 
subject. If the deficit of observed e′ value to the age-
related normal e′ value was greater than the lower 95% 
tolerance interval, the subject was considered having 
diastolic dysfunction [20].
Medical history and physical examination
A standardized medical history, physical examination 
and resting ECG were performed in all subjects. Height 
and weight were obtained, and body mass index (BMI) 
was calculated as body weight (in kg) divided by squared 
height (in meters). Waist circumference was measured 
as the narrowest circumference between the lower rib 
margin and anterior superior iliac crest. Office brachial 
BP was measured twice during two different visits in a 
seated patient, using a standard mercury sphygmoma-
nometer; regular or large adult cuffs were used, depend-
ing on patient arm circumference. The mean value of the 
two measurements was calculated and used for statistical 
analysis.
Analytical procedures
All biochemical parameters (LDL-cholesterol, HDL-cho-
lesterol, triglycerides, glucose) were determined within 
1 week of cardiovascular examination by standard meth-
ods on a Roche-Modular Autoanalyzer (Milan, Italy). 
Glycosylated hemoglobin (HbA1c) was measured by 
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high-performance liquid chromatography and standard-
ized against DCCT standard.
Statistical analysis
Data are expressed as mean  ±  SD, categorical data as 
percentages. Variables with skewed distribution (triglyc-
erides, HbA1c) were summarized as median [interquar-
tile range], and were logarithmically transformed for 
parametric statistical analysis. ANOVA was used to com-
pare continuous variables, and a χ2 test for categorical 
variables. The univariate relationships between the out-
come variables and continuous variables were assessed by 
Pearson’s correlation coefficient. Multiple linear regres-
sion analyses (controlled for sex, current smoking and, in 
T2DM patients, also for BP-lowering, lipid-lowering and 
anti-diabetic treatment) with backward stepwise removal 
were used to identify the independent associations of 
outcome variables with their significant univariate cor-
relates. Statistical tests were two-sided, and significance 
was set at a value of P < 0.05. Statistical analysis was per-
formed by JMP software, version 3.1 (SAS Institute Inc., 
Cary, NC, USA).
Results
Characteristics of the study populations
The two populations were analyzed separately and their 
main characteristics are reported in Table  1. T2DM 
patients and healthy volunteers had comparable age and 
sex distribution. T2DM patients had higher BMI, waist 
circumference, peripheral BP and heart rate, higher 
triglycerides and plasma glucose levels and lower HDL-
cholesterol. Within T2DM patients 66.4% had hyper-
tension, 52.8% were treated by BP-lowering therapy and 
44.0% by lipid-lowering therapy. Table 2 reports cardiac 
and vascular measures in both groups; T2DM patients 
had higher LV mass, LV mass index, prevalence of LVH 
and inappropriate LV mass and decreased ess-MWS as 
Table 1 Characteristics of study populations
T2DM patients Healthy volunteers P
Mean ± SD/median [IQR] Mean ± SD/median [IQR]
Gender (M:F) 82:43 61:40 0.45
Age (years) 58 ± 7 57 ± 8 0.24
Height (cm) 170 ± 9 171 ± 9 0.36
BMI (kg/m2) 28.6 ± 4.2 26.1 ± 3.6 <0.0001
Obesity (%) 26.4 9.0 0.0001
Waist circumference (cm) 104 ± 11 93 ± 10 <0.0001
Heart rate (bpm) 68 ± 11 62 ± 10 <0.0001
Systolic/diastolic BP (mmHg) 138 ± 17/80±9 121 ± 11/75±7 <0.0001
LDL-cholesterol (mmol/L) 2.89 ± 0.72 3.11 ± 0.93 0.10
HDL-cholesterol (mmol/L) 1.28 ± 0.31 1.48 ± 0.34 <0.0005
Triglycerides (mmol/L) 1.33 [0.94] 1.11 [0.73] 0.001
Fasting glucose (mmol/L) 7.0 ± 1.8 5.1 ± 0.5 <0.0001
HbAc1 (%) 7.0 [1.3]
T2DM duration (years) 7.1 ± 6.4
Current smoking (%) 35.2 29.1 0.26
BP-lowering treatment (%) 52.8 0 <0.0001
Lipid-lowering treatment (%) 44.0 0 <0.0001
Table 2 Cardiovascular parameters in study populations
T2DM patients Healthy volunteers P
Mean ± SD Mean ± SD
LV mass (g) 207 ± 41 176 ± 42 <0.005
LV mass index (g/m2.7) 50 ± 11 41 ± 9 <0.0001
LV hypertrophy (%) 51.2 18.6 <0.0001
Inappropriate LV mass 
(%)
56.8 17.6 <0.0001
Ejection fraction (%) 65 ± 7 66 ± 8 0.29
ess-MWS (%) 101 ± 15 108 ± 11 <0.005
Stroke volume (mL) 72 ± 17 76 ± 17 0.15
E/A ratio transmitral 0.90 ± 0.24 1.10 ± 0.27 <0.0001
E/e′ ratio 7.4 ± 2.1 5.9 ± 1.4 <0.0001
e′ velocity (cm/s) 9.4 ± 1.7 11.5 ± 2.2 <0.0001
s′ velocity (cm/s) 9.1 ± 1.4 9.6 ± 1.4 <0.05
cfPWV (m/s) 8.5 ± 1.8 7.1 ± 1.3 <0.0001
ccaPWV (m/s) 8.4 ± 1.8 7.1 ± 1.6 <0.0005
Carotid systolic BP 
(mmHg)
124 ± 14 111 ± 11 <0.0001
Carotid pulse pressure 
(mmHg)
44 ± 13 35 ± 9 <0.0001
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well as longitudinal e′ and s′ velocities. T2DM patients 
had also higher cfPWV, ccaPWV and local carotid BP. 
Thirty-four T2DM patients (27.2%) and 6 healthy vol-
unteers (5.9%; P  <  0.0001) had cfPWV higher than that 
expected for age and mean BP [28].
Univariate correlations
Table  3 reports univariate correlations of e′ velocity, 
cfPWV and LV mass with age, body size, hemodynamic 
and metabolic variables (reported r values with P at 
least  <0.05), separately for T2DM patients and healthy 
volunteers. In healthy volunteers, ccaPWV correlated 
with age, heart rate, systolic BP, LV mass and cfPWV 
(r  =  0.52, 0.21, 0.54, 0.21 and 0.43; P  <  0.05–0.0001), 
and in T2DM patients ccaPWV correlated with waist 
circumference, BMI, heart rate, systolic BP and cfPWV 
(r = 0.22, 0.18, 0.25, 0.38 and 0.21; P < 0.05–0.0001).
In healthy volunteers, the inverse linear rela-
tionship between e′ velocity and age (r  =  −0.60; 
P  <  0.0001) was described by the equation e′ velocity 
(cm/s) = −0.168 * Age (years) + 21.03, and by the lower 
95% tolerance interval of −2.47 cm/s. Applying this equa-
tion and the lower 95% tolerance interval as previously 
described [20], we identified 44 T2DM patients (35.2%) 
Table 3 Univariate correlation coefficients describing the associations of  early diastolic velocity, cfPWV and  LV mass 
with tested parameters in T2DM patients and in healthy volunteers
r value reported when P at least < 0.05
T2DM patients Healthy volunteers
e′ (cm/s) cfPWV (m/s) LV mass (g) e′ (cm/s) cfPWV (m/s) LV mass (g)
cfPWV (m/s) −0.32 – 0.21 −0.47 – 0.26
Carotid systolic BP (mmHg) −0.38 0.44 0.22 −0.58 0.46 0.36
Carotid pulse pressure (mmHg) −0.31 0.26 ns −0.40 0.44 0.29
Age (years) −0.31 0.29 ns −0.61 0.47 0.35
BMI (kg/m2) ns 0.21 0.25 ns ns 0.37
Waist circumference (cm) ns 0.23 0.45 −0.24 0.25 0.45
Heart rate (bpm) −0.25 0.24 0.20 ns 0.22 ns
Stroke volume (mL) 0.19 ns ns ns ns 0.43
LV mass (g) −0.31 0.21 – −0.32 0.26 –
Log triglycerides ns ns ns ns ns ns
LDL-cholesterol (mmol/L) ns ns ns ns ns ns
HDL-cholesterol (mmol/L) ns ns ns ns ns −0.27
Fasting glucose (mmol/L) −0.23 0.18 0.24 −0.29 0.32 ns
Log HbA1c −0.27 0.37 0.39 – – –
T2DM duration (years) ns 0.21 0.34 – – –
Fig. 1 Relationship between s′ and e′ longitudinal velocities in Healthy volunteers and in T2DM patients
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and 8 healthy volunteers (7.9%; P < 0.0001) having dias-
tolic dysfunction.
A correlation between e′ and s′ velocity was observed 
both in healthy volunteers and in T2DM patients (Fig. 1); 
the relationship was stronger and the slope of the regres-
sion line was steeper (P < 0.0001) in healthy subjects than 
in T2DM patients.
Independent determinants of e′ velocity, cfPWV, LV mass 
and ccaPWV
The independence of the associations of e′ velocity, 
cfPWV, LV mass and ccaPWV with their univariate corre-
lates was tested in multiple regression models with step-
wise removal, adjusted for sex and smoking habit and, in 
T2DM patients, also for BP-lowering, lipid-lowering and 
anti-diabetic treatment (Table 4). Early diastolic longitu-
dinal velocity e′ in healthy volunteers was determined by 
age, carotid systolic BP and s′ velocity; in T2DM patients 
it was determined by male sex, age, carotid systolic BP, 
heart rate and LV mass. CfPWV was independently asso-
ciated with age, carotid BP, heart rate and fasting glucose 
in healthy volunteers, and with age, carotid BP, heart rate 
and HbA1c levels in T2DM patients. LV mass was deter-
mined by age, body height, carotid systolic BP and stroke 
volume in healthy volunteers, and by male sex, waist 
circumference, carotid systolic BP, HbA1c levels and 
diabetes duration in T2DM patients. CcaPWV was deter-
mined by age, systolic BP and heart rate in healthy volun-
teers (ß ± SE: 0.34 ± 0.09, 0.34 ± 0.09 and 0.17 ± 0.07; 
cumulative R2 = 0.40; P < 0.0001), and by heart rate, sys-
tolic BP and hypertensive treatment in T2DM patients 
(ß ± SE: 0.21 ± 0.08, 0.32 ± 0.08 and 0.18 ± 0.08; cumu-
lative R2 = 0.21; P < 0.0001).
Poor glycemic control and cardiovascular measures
T2DM patients were divided according to HbA1c levels 
(<6.5% and ≥6.5%) [27]. Table  5 demonstrates that the 
two subgroups were comparable for age, sex and T2DM 
duration. As compared to patients with HbA1c <6.5%, 
patients with HbA1c ≥6.5% had higher carotid systolic 
BP, cfPWV and LVMI, higher prevalence of diastolic 
Table 4 Independent determinants (β ±  SE) of  early diastolic velocity, cfPWV and  LV mass in  T2DM patients and  in 
healthy volunteers 
SBP systolic BP
T2DM patients Healthy volunteers
e′ velocity  
(cm/s)
cfPWV  
(m/s)
LV mass  
(g)
e′ velocity  
(cm/s)
cfPWV  
(m/s)
LV mass  
(g)
Sex (male) 0.19 ± 0.08 0.18 ± 0.08
Age (years) −0.22 ± 0.08 0.22 ± 0.07 −0.37 ± 0.08 0.34 ± 0.10 0.25 ± 0.08
Height (cm) 0.45 ± 0.07
Waist circumference (cm) 0.26 ± 0.07
Carotid SBP (mmHg) −0.25 ± 0.08 0.28 ± 0.07 0.18±0.07 −0.24 ± 0.08 0.26 ± 0.09 0.28 ± 0.08
Heart rate (bpm) −0.24 ± 0.08 0.18 ± 0.07 0.30 ± 0.08
Stroke volume (mL) 0.25 ± 0.07
LV mass (g) −0.25 ± 0.09
s′ velocity (cm/s) 0.43 ± 0.06
Fasting glucose (mmol/L) 0.29 ± 0.08
Log HbA1c 0.25 ± 0.07 0.19 ± 0.08
T2DM duration (years) 0.22 ± 0.07
Cumulative  R2 0.32
P < 0.0001
0.34
P < 0.0001
0.38
P < 0.0001
0.60
P < 0.0001
0.43
P < 0.0001
0.56
P < 0.0001
Table 5 Cardiovascular measures in T2DM patients accord-
ing to HbA1c levels
HbA1c <6.5% HbA1c ≥6.5% P
N 40 85
Age (years) 58 ± 8 58 ± 10 0.74
Male:female 25:15 60:25 0.37
T2DM duration (years) 6.0 ± 5.2 7.6 ± 6.8 0.18
HbAc1 (%) 6.1 ± 0.3 7.6 ± 0.9 <0.0001
Carotid systolic BP (mmHg) 119 ± 13 126 ± 14 0.01
cfPWV (m/s) 8.0 ± 1.5 8.7 ± 1.9 <0.05
Increased cfPWV (%) 15.0 32.9 <0.05
ccaPWV (m/s) 8.3 ± 1.6 8.5 ± 1.8 0.31
LVMI (g/m2.7) 46 ± 10 52 ± 10 0.005
LVH (%) 35.0 58.8 0.01
e′ velocity (cm/s) 10.1 ± 1.6 9.1 ± 1.7 0.001
Diastolic dysfunction (%) 22.5 40.0 <0.05
s′ velocity (cm/s) 9.5 ± 1.5 8.9 ± 1.4 <0.05
ess-MWS (%) 105 ± 13 99 ± 16 <0.05
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dysfunction, increased aortic stiffness and LVH, lower 
e′ and s′ longitudinal velocities and ess-MWS. No dif-
ferences between the two subgroups were observed for 
ccaPWV.
Discussion
In T2DM patients free of cardiovascular disease and with 
preserved LV EF, HbA1c levels were positively associated 
with LV mass and aortic stiffness, both of which showed 
a negative independent impact on early diastolic veloc-
ity e′, the latter through an increase in central systolic 
BP. T2DM patients with suboptimal glycemic control 
(HbA1c ≥ 6.5%) had a higher prevalence of LV diastolic 
dysfunction, together with a higher prevalence of LV 
hypertrophy and increased aortic stiffness.
LV diastolic dysfunction is an early manifestation 
of diabetic heart disease [1, 20, 21], and a subclinical 
impairment of diastolic function is associated with higher 
glucose levels [3, 19, 21]. Chronic increase in plasma glu-
cose levels has been shown to negatively influence LV 
diastolic performance through different mechanisms, 
including alteration in mitochondrial energy metabolism 
and increment in myocardial oxidative stress [10, 11], LV 
mass increase and changes in myocardial composition [7, 
8], acceleration of large artery stiffening and consequent 
increase in vascular load [12–14]. The present study was 
designed to define the interplay between glycemic con-
trol, arterial stiffening, LV hypertrophy and subclinical 
diastolic dysfunction in asymptomatic T2DM patients 
with preserved LV ejection fraction.
Prevalence of impaired LV diastolic function
E′ velocity of mitral annulus is considered a valuable non-
invasive parameter of LV diastolic function, as it reflects 
myocardial relaxation and restoring forces [15, 16] as well 
as myocardial fibrosis [17, 18]. Yet, e′ velocity depends 
strongly on age; with age the magnitude of e′ velocity 
progressively decreases. In order to determine the age-
corrected values for normal e′ velocity, which can be 
used to identify T2DM patients with impaired diastolic 
function, we utilized a previously described method [20] 
employing a linear regression equation describing the 
relationship between e′ velocity and age in healthy vol-
unteers of comparable age and sex distribution. Applying 
this approach, one-third of asymptomatic T2DM patients 
with preserved ejection fraction had e′ velocity lower 
than that expected for age.
HbA1c levels, LV mass, aortic stiffness and e′ velocity
Fasting plasma glucose and HbA1c levels were not inde-
pendently related to e′ velocity, yet HbA1c was directly 
and independently associated with LV mass and aortic 
stiffness, as assessed by cfPWV. The association between 
glycemic control and LV mass has been previously 
described in both non-diabetic and diabetic patients 
[36, 37], and it is supposed to reflect a glucose-induced 
activation of epigenetic mechanism regulating cardio-
myocyte hypertrophy [7], as well as accelerated collagen 
I and III synthesis by cardiac fibroblasts exposed to high 
glucose levels [8]. Increased plasma glucose levels also 
augment the generation of advanced glycation end-prod-
ucts (AGEs), the molecules formed by a nonenzymatic 
reaction between a reducing sugar and an amine group 
of proteins or lipids. AGEs stimulate the expression of 
extracellular matrix genes [38], and the tissue accumula-
tion of AGEs has been shown to be associated with inap-
propriate LV mass increment [39]. In our study, T2DM 
patients, as compared to healthy volunteers of similar 
age, had significantly higher prevalence of inappropri-
ate LV mass (57 vs 18%), i.e. LV mass higher than that 
necessary to sustain the body size and cardiac workload 
[33]. In fact, in healthy volunteers LV mass reflected the 
physiologic adaptation to body height and stroke work 
(a product of stroke volume and afterload), whereas in 
T2DM patients LV mass was determined also by HbA1c 
and T2DM duration (Table 4). Higher resting tension of 
hypertrophied cardiomyocytes together with interstitial 
fibrosis and collagen cross-linking [40] may explain the 
negative impact of LV mass increment on LV diastolic 
function.
The association between glycemic control and aortic 
stiffness is supposed to reflect AGEs-related collagen 
cross-linking within the arterial wall [41]. Stiffening of 
the aortic wall results in unfavorable alterations in central 
hemodynamics, that include an augmentation in forward 
arterial pressure wave amplitude and premature wave 
reflection, both of which increase central systolic BP; 
i.e. LV afterload [42]. A direct effect of afterload on LV 
relaxation has been demonstrated in experimental stud-
ies showing that afterload elevation slows down the LV 
pressure fall during isovolumic relaxation, leading to an 
incomplete myocardial lengthening [13, 14]. The rate of 
LV pressure fall slows in direct proportion to the mag-
nitude of systolic pressure increment [14]. In our study, 
carotid systolic BP was inversely and independently asso-
ciated with e′ velocity, both in healthy volunteers and in 
T2DM patients, and its magnitude was higher in diabetic 
population.
In contrast to aortic stiffness, which was negatively 
influenced by fasting plasma glucose in healthy volun-
teers and by HbA1c in T2DM patients, the local carotid 
stiffness was not independently related to metabolic 
parameters. This finding is consistent with results of pre-
vious studies demonstrating a different impact of modi-
fiable cardiovascular risk factors on aortic and carotid 
stiffness [43, 44].
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It should be emphasized that other T2DM-related fac-
tors, not evaluated in this study, like insulin-resistance 
and altered myocardial metabolism [45, 46], myocardial 
steatosis [47] or autonomic dysfunction [48], might par-
ticipate on the impairment of LV diastolic performance 
in T2DM. In fact, in our T2DM patients, sex, age, carotid 
BP, heart rate and LV mass explained only 32% of e′ 
velocity variance.
Systo‑diastolic coupling and LV systolic performance
Early diastolic longitudinal velocity e′ is determined 
not only by LV relaxation rate but also by restoring 
forces [15, 16] generated during systolic contraction 
of myocardial fibers. Study in anesthetized dogs has 
suggested that the magnitude of restoring forces is 
matched to the force of LV contraction, and that the 
determinants of systolic shortening are also the deter-
minants of e′ velocity [16]. In healthy volunteers of our 
study, s′ and e′ velocities closely correlated each other 
independently of other covariates (Table  4), whereas 
in T2DM patients the association between systolic and 
diastolic velocity was weaker (Fig.  1) and s′ velocity 
did not result an independent determinant of e′. Fur-
thermore, T2DM patients, though having LV EF com-
parable to that of healthy volunteers, showed lower 
longitudinal systolic velocity s′ and ess-MWS. Alto-
gether these findings imply that myocardial metabolic 
and structural changes related to diabetes affect systo-
diastolic coupling and provoke a subclinical decline in 
systolic myocardial performance, both longitudinal and 
circumferential [34].
Glycemic control
Asymptomatic T2DM patients with sub-optimal glyce-
mic control (Hb1Ac ≥ 6.5%) [27] had significantly lower 
diastolic and systolic longitudinal velocities and ess-
MWS together with higher aortic stiffness, central BP 
and LV mass index when compared to those with HbA1c 
<6.5%. These observations are in agreement with pro-
spective studies demonstrating that an improvement in 
glycemic control is paralleled by improvements in LV sys-
tolic and diastolic function [21, 49].
Study limitations
The cross-sectional design of the study cannot elucidate 
cause-and-effect relationships. Silent inducible ischemia 
was not assessed by stress testing in T2DM patients. 
Data on other T2DM-related factors that might influ-
ence LV mass and arterial stiffness, like plasma insulin 
and adiponectin, were not available. In healthy volun-
teers, HbA1c was not determined. LV longitudinal func-
tion was estimated by a simple measure of mitral annulus 
velocity and not by a more complex measurement of LV 
strain, since speckle tracking–based strain imaging has 
low achievable frame rates [15], and since previous stud-
ies have demonstrated a good association of e′ velocity 
with LV relaxation rate and restoring forces [15, 16].
Conclusions
Chronic increase in plasma glucose level in T2DM 
patients is associated with aortic stiffening and conse-
quent increase in LV afterload, as well as with LV mass 
increment. Increase in both LV afterload and mass 
showed a negative impact on e′ longitudinal myocardial 
velocity used as a marker of LV diastolic function. LV 
systo-diastolic coupling and systolic myocardial perfor-
mance seem to be also negatively influenced by diabetes 
and increased plasma glucose, even if the chamber func-
tion is still preserved. An adequate control of plasma glu-
cose level and central BP might prevent the development 
of LV myocardial dysfunction and its eventual transition 
towards heart failure.
Abbreviations
LV: left ventricle; T2DM: type 2 diabetes mellitus; cfPWV: carotid-femoral pulse 
wave velocity; ccaPWV: carotid pulse wave velocity; BMI: body mass index; 
HbA1c: glycosylated hemoglobin; AGEs: advanced glycation end-products.
Authors’ contributions
Authors contributions is as follows: (1) study conception and design (MK, CP, 
AF); (2) conducting the experiments (MK, CM); (3) data analysis and interpreta-
tion (MK, CM, CP); drafting of the manuscript (MK, AF, CP). All authors read and 
approved the final manuscript.
Author details
1 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, 
Italy. 2 Esaote SpA, Genoa, Italy. 3 School of Medicine, Department of Surgical, 
Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, 
Via Savi 10, 56126 Pisa, Italy. 4 Department of Cardiology, University Hospital 
of Wales, Heath Park, Cardiff CF14 4XW, UK. 
Acknowledgements
Not applicable.
Competing interests
MK is responsible of clinical studies for Esaote SpA.
Availability of data and materials
The datasets used and analysed during the current study are available from 
the corresponding author on reasonable request.
Ethics approval and consent to participate
The protocol of the study was approved by the institutional ethics committee 
(Comitato Etico Area Vasta Nord-Ovest, Regione Toscana Pisa; Reference Number: 
3146/2010 and 245/2015). All subjects gave their informed consent to participate.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 15 March 2017   Accepted: 2 June 2017
Page 9 of 10Kozakova et al. Cardiovasc Diabetol  (2017) 16:78 
References
 1. von Bibra H, Sutton MSJ. Diastolic dysfunction in diabetes and the 
metabolic syndrome: promising potential for diagnosis and prognosis. 
Diabetologia. 2010;53:1033–45.
 2. Stratmann B, Tscoepe D. Heart in diabetes: not only a macrovascular 
disease. Diabetes Care. 2011;34(Suppl 2):S138–44.
 3. Sánchez-Barriga JJ, Rangel A, Castañeda R, Flores D, Frati AC, Ramos MA, 
et al. Left ventricular diastolic dysfunction secondary to hyperglycemia in 
patients with type II diabetes. Arch Med Res. 2001;32:44–7.
 4. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, 
CHARM Investigators, et al. Impact of diabetes on outcomes in patients 
with low and preserved ejection fraction heart failure: an analysis of the 
Candesartan in heart failure: assessment of reduction in mortality and 
morbidity (CHARM) programme. Eur Heart J. 2008;29:1377–85.
 5. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, et al. Glycemic 
control and heart failure among adult patients with diabetes. Circulation. 
2001;103:2668–73.
 6. Tsujino T, Kawasaki D, Masuyama T. Left ventricular diastolic dysfunction 
in diabetic patients: pathophysiology and therapeutic implications. Am J 
Cardiovasc Drugs. 2006;6:219–30.
 7. Feng B, Chen S, Chiu J, George B, Chakrabarti S. Regulation of cardiomyo-
cyte hypertrophy in diabetes at the transcriptional level. Am J Physiol 
Endocrinol Metab. 2008;294:E1119–26.
 8. Monnier VM, Sell DR, Abdul-Karim FW, Emancipator SN. Collagen brown-
ing and cross-linking are increased in chronic experimental hyperglyce-
mia. Relevance to diabetes and aging. Diabetes. 1988;37:867–72.
 9. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, 
Kupreishvili K, et al. Diastolic stiffness of the failing diabetic heart: impor-
tance of fibrosis, advanced glycation end products, and myocyte resting 
tension. Circulation. 2008;117:43–51.
 10. Xie J, Cui K, Hao H, Zhang Y, Lin H, Chen Z, Huang X, Cao S, Liao W, Bin J, 
Kitakaze M, Liao Y. Acute hyperglycemia suppresses left ventricular dias-
tolic function and inhibits autophagic flux in mice under prohypertrophic 
stimulation. Cardiovasc Diabetol. 2016;15:136.
 11. Gao X, Xu Y, Xu B, Liu Y, Cai J, Liu HM, Lei S, Zhong YQ, Irwin MG, Xia Z. 
Allopurinol attenuates left ventricular dysfunction in rats with early 
stages of streptozotocin-induced diabetes. Diabetes Metab Res Rev. 
2012;28:409–17.
 12. Reddy GK. AGE-related cross-linking of collagen is associated with aortic 
wall matrix stiffness in the pathogenesis of drug-induced diabetes in rats. 
Microvasc Res. 2004;68:132–42.
 13. Leite-Moreira AF, Correia-Pinto J, Gillebert TC. Afterload induced changes 
in myocardial relaxation: a mechanism for diastolic dysfunction. Cardio-
vasc Res. 1999;43:344–53.
 14. Gillebert TC, Lew WYW. Influence of systolic pressure profile on rate of left 
ventricular pressure fall. Am J Physiol. 1991;261:H805–13.
 15. Flachskampf FA, Biering-Sørensen T, Solomon SD, Duvernoy O, Bjerner T, 
Smiseth OA. Cardiac imaging to evaluate left ventricular diastolic func-
tion. JACC Cardiovasc Imaging. 2015;8:1071–93.
 16. Opdahl A, Remme EW, Helle-Valle T, Lyseggen E, Vartdal T, Pettersen E, 
et al. Determinants of left ventricular early-diastolic lengthening velocity: 
independent contributions from left ventricular relaxation, restoring 
forces, and lengthening load. Circulation. 2009;119:2578–86.
 17. Kosmala W, Przewlocka-Kosmala M, Wojnalowicz A, Mysiak A, Marwick TH. 
Integrated backscatter as a fibrosis marker in the metabolic syndrome: 
association with biochemical evidence of fibrosis and left ventricular 
dysfunction. Eur Heart J Cardiovasc Imaging. 2012;13:459–67.
 18. Querejeta R, Varo N, López B, Larman M, Artiñano E, Etayo JC, et al. 
Serum carboxy-terminal propeptide of procollagen type I is a marker 
of myocardial fibrosis in hypertensive heart disease. Circulation. 
2000;101:1729–35.
 19. Patil VC, Patil HV, Shah KB, Vasani JD, Shetty P. Diastolic dysfunction in 
asymptomatic type 2 diabetes mellitus with normal systolic function. J 
Cardiovasc Dis Res. 2011;2:213–22.
 20. von Bibra H, Paulus WJ, Sutton MSJ, Leclerque C, Schuster T, Schumm-
Draeger PM. Quantification of diastolic dysfunction via the age depend-
ence of diastolic function—impact of insulin resistance with and without 
type 2 diabetes. Int J Cardiol. 2015;182:368–74.
 21. Leung M, Wong VW, Hudson M, Leung DY. Impact of improved glycemic 
control on cardiac function in type 2 diabetes mellitus. Circ Cardiovasc 
Imaging. 2016;9:e003643.
 22. Weber T, O’Rourke MF, Ammer M, Kvas E, Punzengruber C, Eber B. Arterial 
stiffness and arterial wave reflections are associated with systolic and 
diastolic function in patients with normal ejection fraction. Am J Hyper-
tens. 2008;21:1194–202.
 23. Borges MC, Colombo RC, Gonçalves JG, de Oliveira Ferreira J, Franchini 
KG. Longitudinal mitral annulus velocities are reduced in hypertensive 
subjects with or without left ventricle hypertrophy. Hypertension. 
2006;47:854–60.
 24. Hills SA, Balkau B, Coppack SW, Dekker JM, Mari A, Natali A, et al. The 
EGIR-RISC Study (The European group for the study of insulin resistance; 
relationship between insulin sensitivity and cardiovascular risk): I. Meth-
odology and objectives. Diabetologia. 2004;47:566–70.
 25. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. 
Recommendations for cardiac chamber quantification by echocardiogra-
phy in adults: an update from the American Society of Echocardiography 
and the European Association of Cardiovascular Imaging. J Am Soc 
Echocardiogr. 2015;28:1–39.
 26. Sharifov OF, Schiros CG, Aban I, Denney TS, Gupta H. Diagnostic accuracy 
of tissue Doppler index e/e′ for evaluating left ventricular filling pressure 
and diastolic dysfunction/heart failure with preserved ejection fraction: a 
systematic review and meta-analysis. J Am Heart Assoc. 2016;5:1–6.
 27. American Diabetes Association. 2. Classification and diagnosis of diabe-
tes. Diabetes Care. 2016;39(Suppt 1):S13–22.
 28. Mattace-Raso F, Hofman A, Verwoert GC, Wittemana JC, Wilkinson I, 
Cockcroft J, et al. Determinants of pulse wave velocity in healthy people 
and in the presence of cardiovascular risk factors: establishing normal 
and reference values. Eur Heart J. 2010;31:2338–50.
 29. Palombo C, Kozakova M, Guraschi N, Bini G, Cesana F, Castoldi G, et al. 
Radiofrequency-based carotid wall tracking: a comparison between two 
different systems. J Hypertens. 2012;30:1614–9.
 30. Bramwell JC, Hill AV. The velocity of the pulse wave in man. Proc R Soc 
Lond B. 1922;93:298–306.
 31. Van Bortel LM, Balkestein EJ, van der Heijden-Spek JJ, Vanmolkot FH, 
Staessen JA, Kragten JA, et al. Non-invasive assessment of local arterial 
pulse pressure: comparison of applanation tonometry and echo-tracking. 
J Hypertens. 2001;19:1037–44.
 32. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. 
Echocardiographic assessment of left ventricular hypertrophy: compari-
son to necropsy findings. Am J Cardiol. 1986;57:450–8.
 33. de Simone G, Verdecchia P, Pede S, Gorini M, Maggioni AP. Prognosis 
of inappropriate left ventricular mass in hypertension: the MAVI Study. 
Hypertension. 2002;40:470–6.
 34. Devereux RB, Roman MJ, Paranicas M, O’Grady MJ, Lee ET, Welty TK, et al. 
Impact of diabetes on cardiac structure and function: the strong heart 
study. Circulation. 2000;101:2271–6.
 35. Chahal NS, Lim TK, Jain P, Chambers JC, Kooner JS, Senior R. Normative 
reference values for tissue Doppler imaging parameters of left ventricular 
function: a population-based study. Eur J Echocardiogr. 2010;11:51–6.
 36. Sciacqua A, Miceli S, Carullo G, Greco L, Succurro E, Arturi F, et al. One-
hour postload plasma glucose levels and left ventricular mass in hyper-
tensive patients. Diabetes Care. 2011;34:1406–11.
 37. Felicio JS, Pacheco JT, Ferreira SR, Plavnik F, Moisés VA, Kohlmann O Jr, 
et al. Hyperglycemia and nocturnal systolic blood pressure are associated 
with left ventricular hypertrophy and diastolic dysfunction in hyperten-
sive diabetic patients. Cardiovasc Diabetol. 2006;5:19.
 38. Striker LJ, Striker GE. Administration of AGEs in vivo induces extracellular 
matrix gene expression. Nephrol Dial Transplant. 1996;11(Suppl 5):62–5.
 39. Wang CC, Wang YC, Wang GJ, Shen MY, Chang YL, Liou SY, et al. Skin 
autofluorescence is associated with inappropriate left ventricular mass 
and diastolic dysfunction in subjects at risk for cardiovascular disease. 
Cardiovasc Diabetol. 2017;16:15–25.
 40. Borbély A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, 
et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 
2005;111:774–81.
 41. Ferreira MT, Leite NC, Cardoso CR, Salles GF. Correlates of aortic stiffness 
progression in patients with type 2 diabetes: importance of glycemic 
control: the Rio de Janeiro type 2 diabetes cohort study. Diabetes Care. 
2015;38:897–904.
 42. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, et al. Aortic 
stiffness, blood pressure progression, and incident hypertension. JAMA. 
2012;308:875–81.
Page 10 of 10Kozakova et al. Cardiovasc Diabetol  (2017) 16:78 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 43. Kozakova M, Morizzo C, Guarino D, Federico G, Miccoli M, Giannattasio 
C, et al. The impact of age and risk factors on carotid and carotid-femoral 
pulse wave velocity. J Hypertens. 2015;33:1446–51.
 44. Paini A, Boutouyrie P, Calvet D, Tropeano AI, Laloux B, Laurent S. Carotid 
and aortic stiffness: determinants of discrepancies. Hypertension. 
2006;47:371–6.
 45. Novo G, Manno G, Russo R, Buccheri D, Dell’Oglio S, Morreale P, et al. 
Impact of insulin resistance on cardiac and vascular function. Int J Cardiol. 
2016;221:1095–9.
 46. Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, Romijn 
JA, de Roos A, Radder JK. Diastolic dysfunction is associated with 
altered myocardial metabolism in asymptomatic normotensive patients 
with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol. 
2003;42:328–35.
 47. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, 
et al. Myocardial steatosis is an independent predictor of diastolic dys-
function in type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52:1793–9.
 48. Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy 
in patients with diabetes mellitus. World J Diabetes. 2014;5:17–39.
 49. Grandi AM, Piantanida E, Franzetti I, Bernasconi M, Maresca A, Marnini P, 
et al. Effect of glycemic control on left ventricular diastolic function in 
type 1 diabetes mellitus. Am J Cardiol. 2006;97:71–6.
